CaMKII regulates key mechanisms of vascular response to injury in vivo
CaMKII regulates key mechanisms of vascular response to injury in vivo
批准号:
9029343
负责人:
Isabella Maria Grumbach
金额:
$37.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-16 至 2017-12-14
关键词:
AtherosclerosisBalloon AngioplastyBindingBlood VesselsCalmodulinCardiovascular systemCause of DeathCoronary Artery BypassDataDependenceDevelopmentDiseaseDisease ResistanceEndarterectomyEndotheliumEnzymesEquilibriumEventFosteringGoalsGrowthHealthHealth Care CostsHyperplasiaIn VitroInjuryKnowledgeLeadLigationMediatingMedicineMissionMorbidity - disease rateMuscle ContractionMyocardial InfarctionOperative Surgical ProceduresOutcomePathway interactionsPhosphotransferasesPrevention strategyProtein-Serine-Threonine KinasesPublic HealthPublishingRegulationResearchRoleSignal TransductionSiteStentsStrokeTestingTherapeuticTranslatingValidationVascular Smooth MuscleVein graftWorkbasecalmodulin-dependent protein kinase IIcytokinedesigngraft failureimprovedin vivoin vivo Modelinhibitor/antagonistinnovationmeetingsmethionine sulfoxide reductasemigrationneointima formationnovelnovel strategiesoxidationpreventprogramsresponseresponse to injuryrestenosistool
中文摘要
描述(由申请人提供):多功能Ca2+/钙调素依赖性激酶II (CaMKII)的功能在脉管系统中仍然知之甚少。我们的数据表明,CaMKII在血管损伤后介导新内膜形成和重塑中起重要作用。冠状动脉搭桥术、球囊血管成形术和外科动脉内膜切除术后静脉移植失败发生新内膜形成和重塑,并在发病率和医疗费用方面产生重大影响。我们的长期目标是研究CaMKII在血管系统中的功能,特别是CaMKII调节作为治疗血管损伤的新途径。本应用的目的是确定CaMKII在损伤中是如何被激活的,直接测试CaMKII抑制是否会在血管损伤中赋予抗病能力,并描述VSMC迁移和增殖对CaMKII氧化激活的依赖。本应用的中心假设是,CaMKII在血管损伤中被Met281/282氧化激活,CaMKII的氧化激活是新生内膜增生、VSMC增殖和迁移所必需的。这一假设是基于我们的初步数据,即CaMKII在损伤后的新内膜形成和重塑中是必不可少的。氧化CaMKII (ox-CaMKII)在血管损伤后的新生内膜中很容易检测到。此外,我们有令人信服的证据表明,损伤反应中的关键激活剂在体外诱导ox-CaMKII。这项研究的基本原理是,了解CaMKII在血管损伤后是如何被激活的,有可能转化为更好的策略来预防血管损伤后的有害影响。在强有力的初步数据的指导下,中心假设将在三个具体目标中进行检验:1)
英文摘要
DESCRIPTION (provided by applicant): The function of the multifunctional Ca2+/calmodulin-dependent kinase II (CaMKII) remains poorly understood in the vasculature. Our data suggest that CaMKII is instrumental in mediating neointima formation and remodeling after vascular injury. Neointima formation and remodeling occur in vein graft failure after coronary artery bypass surgery, after balloon angioplasty and surgical endarterectomy and have a significant impact in terms of morbidity and health care cost. Our long-term goal is to study the function of CaMKII in the vasculature, specifically CaMKII modulation as new approach to treat vascular injury. The objective of this application is to determine how CaMKII is activated in injury, directy test whether CaMKII inhibition will confer disease resistance in vascular injury and delineate the dependance of VSMC migration and proliferation upon the oxidative activation of CaMKII. The central hypothesis of this application is that CaMKII is activated by oxidation of Met281/282 in vascular injury and that oxidative activation of CaMKII is necessary for neointimal hyperplasia, VSMC proliferation and migration. This hypothesis is based on our preliminary data that CaMKII is essential in neointima formation and remodeling after injury. Oxidized CaMKII (ox-CaMKII) is readily detected in the neointima after vascular injury. In addition, we have compelling evidence that key activators in the response to injury induce ox-CaMKII in vitro. The rationale of the proposed research is that understanding how CaMKII is activated after vascular injury, has the potential to translate into better strategies to prevent the deleterious effects after vascular injry. Guided by strong preliminary data, the central hypothesis will be tested in three specific aims: 1)
Dissect the mechanisms of CaMKII activation in vascular injury in vivo; 2) Determine the role of methionine sulfoxide reductase A (MsrA), the enzyme that controls the balance between active ox-CaMKII and reduced inactive CaMKII, in the response to injury; 3) Dissect the mechanisms of CaMKII activation in VSMC migration, proliferation in vitro. In the first aim, a novel in vivo model will be used to test if the blockade of oxidative CaMKII activation is sufficient to abrogate
the response to injury. Under aim 2, we will define whether MsrA can modulate neointimal hyperplasia through ox-CaMKII. In aim 3, we will delineate how CaMKII is activated by key cytokines and growth factors relevant for vascular injury in vitro and how the activation pathways correlate with VSMC migration and proliferation. The approach is innovative because of its use of novel in vivo models and specific tools to dissect CaMKII signaling. The proposed research is significant because it is expected to advance the field by identifying CaMKII activating events in vivo. Ultimately, such knowledge may allow for the development of new preventive strategies for vascular injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia
-
批准号:10531906
-
项目类别:
-
资助金额:$62.54万
-
财政年份:2021
-
负责人:Isabella Maria Grumbach
-
依托单位:
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia
-
批准号:10384519
-
项目类别:
-
资助金额:$62.54万
-
财政年份:2021
-
负责人:Isabella Maria Grumbach
-
依托单位:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
-
批准号:10160909
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2020
-
负责人:Isabella Maria Grumbach
-
依托单位:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
-
批准号:10397594
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2020
-
负责人:Isabella Maria Grumbach
-
依托单位:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced cognitive decline
-
批准号:10282945
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2020
-
负责人:Isabella Maria Grumbach
-
依托单位:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
-
批准号:10615636
-
项目类别:
-
资助金额:$48.95万
-
财政年份:2020
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII as a regulator of diabetic retinopathy
-
批准号:9468258
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII as a regulator of diabetic retinopathy
-
批准号:8820648
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII as a regulator of diabetic retinopathy
-
批准号:8996072
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII regulates key mechanisms of vascular response to injury in vivo
-
批准号:8459392
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2012
-
负责人:Isabella Maria Grumbach
-
依托单位:
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasia
-
批准号:10063535
-
项目类别:
-
资助金额:$43.84万
-
财政年份:2012
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII regulates key mechanisms of vascular response to injury in vivo
-
批准号:8644309
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2012
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII regulates key mechanisms of vascular response to injury in vivo
-
批准号:8293991
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2012
-
负责人:Isabella Maria Grumbach
-
依托单位:
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease
-
批准号:10250744
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodeling
-
批准号:9346799
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease
-
批准号:10447052
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease
-
批准号:10557667
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII mediates vascular smooth cell hypertrophy and hypertension
-
批准号:8262622
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
CaMKII mediates vascular smooth cell hypertrophy and hypertension
-
批准号:8195605
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease
-
批准号:10662341
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Isabella Maria Grumbach
-
依托单位:
海外基金